Galecto (GLTO)

• Market cap: $36.2M
• 1 day: -4.84%
• 5 days: -5.71%
• 1 month: 6.44%
• 3 months: 280.98%
• 6 months: 565.59%
• Year to date: 3.71%
• 1 year: 343.73%
• 5 years: -92.67%
• 10 years: -93.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Employees: 5